Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027627 (
metastases
)
103,950
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Nasopharyngeal carcinoma (NPC) is a highly
metastatic cancer
prevalent in Southern China and Southeast Asia. The current knowledge on the molecular pathogenesis of NPC is still inadequate to improve disease management. Using gene expression microarrays, we have identified the
four-jointed box 1
(
FJX1
) gene to be upregulated in primary NPC tissues relative to nonmalignant tissues. An orthologue of human
FJX1
, the
four-jointed (fj)
gene in Drosophila and
Fjx1
in mouse, has reported to be associated with cancer progression pathways. However, the exact function of
FJX1
in human is not well characterized. The overexpression of
FJX1
mRNA was validated in primary NPC tissue samples, and the level of
FJX1
protein was significantly higher in a subset of NPC tissues (42%) compared to the normal epithelium, where no expression of
FJX1
was observed (
p
= 0.01).
FJX1
is also found to be overexpressed in microarray datasets and TCGA datasets of other cancers including head and neck cancer, colorectal, and ovarian cancer. Both siRNA knockdown and overexpression experiments in NPC cell lines showed that
FJX1
promotes cell proliferation, anchorage-dependent growth, and cellular invasion. Cyclin D1 and E1 mRNA levels were increased following
FJX1
expression indicating that
FJX1
enhances proliferation by regulating key proteins governing the cell cycle. Our data suggest that the overexpression of
FJX1
contributes to a more aggressive phenotype of NPC cells and further investigations into
FJX1
as a potential therapeutic target for NPC are warranted. The evaluation of
FJX1
as an immunotherapy target for NPC and other cancers is currently ongoing.
...
PMID:An Oncogenic Role for Four-Jointed Box 1 (FJX1) in Nasopharyngeal Carcinoma. 3123 44